TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19011946
Drug: No preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preoperative chemoradiation therapy (non-CRT)
Study: 9084062
Drug: CI-988 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-988 (50 mg)
Study: 9084062
Drug: CI-988 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-988 (100 mg)
Study: 2410320
Drug: Dioctyl sodium
Normalized name: Dioctyl sodium sulfosuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioctyl sodium sulfosuccinate (DSS) 100 mg three times daily for 4 days
Study: 2410320
Drug: Dioctyl sodium
Normalized name: Dioctyl sodium sulfosuccinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioctyl sodium sulfosuccinate (DSS) 100 mg three times daily for 7 days
Study: 26890230
Drug: Mirror Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirror Therapy (MT) combined with Neuromuscular Electrical Stimulation (NMES) and conventional physical therapy
Study: 22069972
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) 3.5 mL intra-knee-articular injections
Study: 22069972
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (SH) 2 mL intra-knee-articular injections
Study: 19320670
Drug: Internet-based interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based interventions (IBI) for problem drinking; specific dosage and duration not mentioned.
Study: 19320670
Drug: Check Your
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Check Your Drinking screener (IBI for problem drinkers); specific dosage and duration not mentioned.
Study: 11907839
Drug: Methotrexate 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 0.25% gel
Study: 9036910
Drug: Intra-articular triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular triamcinolone acetonide (3 injections at day 1, 8, and 22 over 4 weeks)
Study: 112944
Drug: Intravenous protirelin
Normalized name: PROTIRELIN
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous protirelin (0.5 mg)
Study: 112944
Drug: Niacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin (2 mg)
Study: 30937431
Drug: Low-dose computed
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose computed tomography (LDCT) screening beyond 5 years
Study: 17678670
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (n=7), twice a week for 6 weeks, including dumbbell bicep curls, wrist flexions, and wrist extensions
Study: 12733373
Drug: Domestic intravenous
Normalized name: domestic cow dander extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic intravenous Turbutalin Sulfate
Study: 9677793
Drug: Ketorolac (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (30 mg as a priming dose and 90 mg infused over 24 hours)
Study: 9677793
Drug: Tramadol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (100 mg + 300 mg)
Study: 9677793
Drug: Buprenorphine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0.3 mg + 0.9 mg)
Study: 9677793
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ketorolac and buprenorphine (30 mg of K as priming dose and 60 + 0.6 mg in infusion)
Study: 7837949
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg orally every 8 h for 36 h)
Study: 3421264
Drug: Labetalol pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol pretreatment (20 mg IV followed by 10 mg increments up to 1 mg/kg)
Study: 31914034
Drug: So-Cheong-Ryong-Tang (SCRT)
Normalized name: SO-101
DrugBank: SO-101 (DB05345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: So-Cheong-Ryong-Tang (SCRT) administered 3 times a day for 4 weeks
Study: 22900583
Drug: Prasugrel (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (10 mg) with Ritonavir (100 mg)
Study: 22900583
Drug: Ritonavir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (100 mg)
Study: 21626525
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (24, 48, or 72 weeks)
Study: 21626525
Drug: Variable therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable therapy (24, 48, or 72 weeks)
Study: 21626525
Drug: IL28B type
Normalized name: adenovirus, type 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL28B type (CC, CT, TT)
Study: 17239870
Drug: Phenazopyridine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenazopyridine (200 mg)
Study: 9484873
Drug: Grepafloxacin 200
Normalized name: grepafloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 200 mg
Study: 9484873
Drug: Grepafloxacin 400
Normalized name: grepafloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 400 mg
Study: 10991830
Drug: Grepafloxacin 600
Normalized name: grepafloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grepafloxacin 600 mg
Study: 29503217
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy-based pain management program
Study: 27561981
Drug: Immediate postpartum
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate postpartum insertion of the etonogestrel-releasing contraceptive implant
Study: 27561981
Drug: 6-week postpartum
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6-week postpartum insertion of the etonogestrel-releasing contraceptive implant
Study: 25799024
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral Internet-based intervention, 2 weekly 45-minute sessions over 5 weeks (10 sessions total)
Study: 12480038
Drug: Propafenone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone SR 425 mg twice daily
Study: 12480038
Drug: Propafenone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone SR 325 mg twice daily
Study: 14556870
Drug: Propafenone SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone SR 225 mg twice daily
Study: 8836744
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly contact to equalize attention)
Study: 1389953
Drug: Medifoxamine 300-1000
Normalized name: Medifoxamine
DrugBank: Medifoxamine (DB13219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medifoxamine 300-1000 mg
Study: 1389953
Drug: Timolol 20
Normalized name: timolol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 20 mg
Study: 23067317
Drug: Levofloxacin-containing 7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-containing 7-day triple therapy (Levo triple)
Study: 23067317
Drug: Standard sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard sequential therapy (SST-10)
Study: 23067317
Drug: Levofloxacin-containing sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin-containing sequential therapy (Levo-ST-10)
Study: 18630547
Drug: Acupuncture compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture compound anesthesia (electroacupuncture combined with intramuscular injection of Pethidine)
Study: 18630547
Drug: Simple Pethidine
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple Pethidine (intramuscular injection)
Study: 19186718
Drug: Acupuncture compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture compound anesthesia
Study: 16195767
Drug: Lipid Replacement
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid Replacement Therapy plus antioxidants
Study: 10363733
Drug: Sparfloxacin (400-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin (400-mg loading dose followed by 200 mg once daily)
Study: 1778879
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g ceftriaxone iv once daily for three days
Study: 1778879
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g ceftriaxone iv once daily for three days
Study: 1778879
Drug: Chloramphenicol 3
Normalized name: chloramphenicol 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloramphenicol 3 g daily in divided doses for two days followed by 2 g daily for 12 days
Study: 6980231
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg oxaprozin (600 mg twice daily)
Study: 6980231
Drug: 3900 mg
Normalized name: aspirin 3900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3900 mg aspirin (975 mg four times a day)
Study: 20537469
Drug: Normal compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal compression pressure garment therapy
Study: 20537469
Drug: Low compression
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low compression pressure garment therapy
Study: 14693987
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption (4 glasses of whisky, 40 g ethanol daily)
Study: 12563776
Drug: Artesunate 6
Normalized name: artesunate 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate 6 mg/kg once every 2 weeks for 4 times
Study: 8547549
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl (55 micrograms/kg) anesthesia
Study: 8547549
Drug: High-dose fentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fentanyl (55 micrograms/kg) anesthesia + thoracic epidural analgesia
Study: 8547549
Drug: Low-dose fentanyl
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fentanyl (15 micrograms/kg) anesthesia + thoracic epidural analgesia
Study: 2230578
Drug: HRCh (local
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRCh (local ultra‐high frequency hyperthermia in combination with radiotherapy and chemotherapy)
Study: 2230578
Drug: RCh (radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCh (radiotherapy and chemotherapy)
Study: 773416
Drug: Prophylactic factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic factor VIII therapy (infusions given once weekly to achieve a post-infusion plasma concentration of at least 0.25 I.U./ml)
Study: 28527129
Drug: Plerixafor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (240 µg/kg/day) + G‐CSF (filgrastim, 400 µg/m2/day) for 4 days
Study: 28527129
Drug: G‐CSF alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF alone (G group)
Study: 25125385
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) plus Hydroxychloroquine (HCQ)
Study: 20174466
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) alone
Study: 25125385
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) plus Clopidogrel (CLOP)
Study: 25125385
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) alone or in combination with ASA
Study: 21562238
Drug: Zinc supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplement (15 mg zinc as ZnSO4)
Study: 21562238
Drug: Control (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (200 g/d of wheat bread fortified with iron and folic acid, no zinc)
Study: 21562238
Drug: Moderate zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate zinc fortification (7.5 mg zinc as ZnO)
Study: 21562238
Drug: High zinc
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High zinc fortification (15 mg zinc as ZnO)
Study: 19221190
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus vitamin D supplementation (1,000 mg of elemental calcium carbonate and 400 IU of vitamin D(3) daily)
Study: 12678187
Drug: Venoruton (hydroxyethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venoruton (hydroxyethyl rutosides) 1 g twice daily for 3 days (2 days before the flight and the day of the flight)
Study: 7981011
Drug: Quinapril 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 2.5 mg p.o.
Study: 24067395
Drug: Intravenous myo-inositol
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous myo-inositol at 60 mg/kg
Study: 24067395
Drug: Intravenous myo-inositol
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous myo-inositol at 120 mg/kg
Study: 19515113
Drug: Prescription drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drugs and dietary supplements
Study: 19515113
Drug: Prescription drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drugs
Study: 19515113
Drug: Estrogen preparations
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen preparations
Study: 19515113
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs, thyroid drugs, and estrogens
Study: 19515113
Drug: Drugs for
Normalized name: DRUGS FOR CONSTIPATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs for diabetes mellitus
Study: 11275667
Drug: Modified Atraumatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Atraumatic Restorative Treatment (ART)
Study: 29925421
Drug: S-amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine (2.5 mg) plus chlorthalidone (25 mg)
Study: 29925421
Drug: S-amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-amlodipine (2.5 mg) plus telmisartan (40 mg)
Study: 26791992
Drug: Computerized medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized medication reviews conducted by expert teams
Study: 20119816
Drug: Orlistat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat (120 mg, 3 times daily) with dietary treatment
Study: 20119816
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment only
Study: 16460484
Drug: rabeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole, amoxicillin, and minocycline
Study: 16460484
Drug: rabeprazole, amoxicillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole, amoxicillin, and clarithromycin
Study: 7803769
Drug: Somatostatin receptor
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin receptor scintigraphy with 111In-labeled octreotide
Study: 3378560
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with levodopa and bromocriptine
Study: 8375429
Drug: Bromocriptine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine monotherapy
Study: 5811680
Drug: Fluid therapy
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid therapy with 2 litres of Ringer‐lactate solution transfused in one hour during surgery.
Study: 5811680
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving 2 litres of Ringer‐lactate solution transfused in one hour.
Study: 31785190
Drug: Repetitive Transcranial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) plus Multicomponent Therapy (MT)
Study: 31785190
Drug: Multicomponent Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent Therapy (MT) alone
Study: 31625118
Drug: No beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blocker use
Study: 27753739
Drug: Rutoside (600-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rutoside (600-1200 mg.d) and hydrolytic enzymes (540-1080 mg.d bromelain, 288-576 mg.d trypsin)
Study: 18305926
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of MDMA and ethanol
Study: 3661647
Drug: Q-switched Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched Nd:YAG laser treatment
Study: 23548852
Drug: Multidisciplinary stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary stress treatment programme (9 sessions over 3 months, including mindfulness-based stress reduction course for 2 hours a week over 8 weeks)
Study: 21040559
Drug: Multidisciplinary stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary stress treatment programme
Study: 23548852
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control group (12 consultations with a psychologist)
Study: 21617185
Drug: Metreleptin administration
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metreleptin administration for 16 weeks
Study: 14566003
Drug: E5564, 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5564, 3.5 mg/h x 72 h
Study: 14566003
Drug: E5564, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5564, 3 mg/h x 4 h
Study: 14566003
Drug: E5564, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5564, 0.5 mg/h x 4 h
Study: 14566003
Drug: E5564, 252
Approvals — FDA: no, EMA: no, PMDA: no
Description: E5564, 252 mg after 72-h infusion
Study: 2893190
Drug: Short-course prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-course prednisone therapy (60 mg/m2 per 24 h until proteinuria disappeared for 3 days, then 40 mg/m2 per 48 h until complete remission)
Study: 2893190
Drug: Standard prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard prednisone therapy (60 mg/m2 per 24 h for 4 weeks, then 40 mg/m2 per 48 h for 4 weeks)
Study: 2893190
Drug: Short-course prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-course prednisone therapy
Study: 8482290
Drug: Standard prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard prednisone therapy
Study: 28185318
Drug: Calcineurin Inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin Inhibitor (CNI)
Study: 26603745
Drug: Self-management of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management of blood pressure (self-monitoring with self-titration of antihypertensive medication)
Study: 25091790
Drug: De-escalation of
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation of empirical antimicrobial treatment
Study: 25091790
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of empirical antimicrobial treatment
Study: 2776869
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg terbutaline from a Turbuhaler inhaled as fast as possible (mean peak inspiratory flow rate = 53 l.min-1)
Study: 2776869
Drug: Simple inhalation
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple inhalation technique with terbutaline Turbuhaler
Study: 735294
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous Propranolol
Study: 735294
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intravenous Metoprolol
Study: 31083176
Drug: Venlafaxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine treatment for 6 weeks
Study: 19783397
Drug: BCTS-S inhalation
Normalized name: S-2 Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCTS-S inhalation of 5 mg morphine HCl
Study: 19783397
Drug: BCTS-MC inhalation
Normalized name: MC-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCTS-MC inhalation of 5 mg morphine HCl
Study: 16444450
Drug: 40 mg/d
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/d pravastatin
Study: 7971538
Drug: Life-style modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-style modification program (5 weekly 90-min sessions on modifying eating and exercise patterns)
Study: 3528451
Drug: Pressure-controlled probing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-controlled probing (50 g vertical force)
Study: 15998266
Drug: Zinc citrate/triclosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc citrate/triclosan formulation with bromochlorophene
Study: 15998266
Drug: Zinc citrate/triclosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc citrate/triclosan formulation without bromochlorophene
Study: 11360593
Drug: Diet control
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet control and insulin therapy (treated group)
Study: 8685072
Drug: Fluvoxamine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (150 mg day(-1))
Study: 8685072
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg day(-1))
Study: 8685072
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (TCA or neuroleptic treatment without SSRI)
Study: 31618444
Drug: Guideline-concordant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-concordant treatment
Study: 30478103
Drug: Online Climate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Climate Schools: Ecstasy and Emerging Drugs module (4 lessons over 4 weeks)
Study: 30478103
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose (completed all four lessons)
Study: 30478103
Drug: Incomplete dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete dose (≤three lessons)
Study: 27469482
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) HF therapy